Alvin J. Siteman Cancer Center · US
Area of research
Cancer Research · Pathology and Forensic Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Lymphoma Diagnosis and Treatment, Genomics and Rare Diseases, and Genetic factors in colorectal cancer.
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase
A community approach to the cancer-variant-interpretation bottleneck
GA4GH: International policies and standards for data sharing across genomic research and healthcare
The GA4GH Variation Representation Specification: A computational framework for variation representation and federated identification
griffithlab/pVACtools: 2.0.0
Evolution of the open-access CIViC knowledgebase is driven by the needs of the cancer variant interpretation community
Integration of the Drug–Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Wikidata as a knowledge graph for the life sciences
Best practices for bioinformatic characterization of neoantigens for clinical utility
griffithlab/pVACtools: 1.5.0
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
The prognostic effects of somatic mutations in ER-positive breast cancer
DGIdb 3.0: a redesign and expansion of the drug–gene interaction database
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth
Epigenetic and transcriptional determinants of the human breast
Erratum to: Modeling precision treatment of breast cancer
Hippo Signaling Influences HNF4A and FOXA2 Enhancer Switching during Hepatocyte Differentiation
Modeling precision treatment of breast cancer
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers